EGFR and neoplasm: Therefore, we hypothesized that incorporating imaging with EGFR-specific radioligands into routine clinical practice may not only facilitate a noninvasive, real-time measurement of EGFR expression across the patient’s entire tumor burden but also allow for dynamic monitoring of cetuximab-mediated receptor downregulation, providing a marker for adequate treatment dosing.